

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
**WO 01/97827 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**,  
38/04, 39/395, 39/00, A01N 63/00, C07K 7/00, 16/00,  
C12N 5/06, 5/08

(74) Agents: **GRANT, Alan, J.** et al.; Carella, Byrne, Bain,  
Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road,  
Roseland, NJ 07068 (US).

(21) International Application Number: PCT/US01/19207

(22) International Filing Date: 15 June 2001 (15.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/212,213 16 June 2000 (16.06.2000) US  
60/212,165 16 June 2000 (16.06.2000) US

(71) Applicants (for all designated States except US): **AR-  
GONEX PHARMACEUTICALS** [US/US]; Suite 1,  
706 Forest Street, Charlottesville, VA 22903 (US). **UNI-  
VERSITY OF VIRGINIA PATENT FOUNDATION**  
[US/US]; 1224 West Main Street, Suite 1-110, Char-  
lottesville, VA 22903 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WHITE, Forest**  
[US/US]; 2001 Locke Lane, Charlottesville, VA 22911  
(US). **HUNT, Donald, F.** [US/US]; 970 Old Ballard Road,  
Charlottesville, VA 22901 (US). **SHABANOWITZ,  
Jeffrey** [US/US]; 914 Tilman Road, Charlottesville, VA  
22901 (US). **ROSS, Mark** [US/US]; 2290 Rocky Run,  
Charlottesville, VA 22901 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- with sequence listing part of description published sepa-  
rately in electronic form and available upon request from  
the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MHC PEPTIDES OVER-EXPRESSED ON PROSTATE CANCER CELLS AND METHODS OF USE

(57) Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially prostate carcinomas. The invention discloses peptides polypeptides, and polynucleotides that can be used to stimulate a CTL response against such cancers.

WO 01/97827 A1



## **MHC PEPTIDES OVER-EXPRESSED ON PROSTATE CANCER CELLS AND METHODS OF USE**

5

This application claims priority of U.S. provisional applications 60/212,213, filed 16 June 2000, and 60/212,615, filed 16 June 2000, the disclosures of both of which are hereby incorporated by reference in their  
10 entirety.

### **FIELD OF THE INVENTION**

15

The present invention relates generally to the field of immunogens and peptide expression in cancerous cells of the prostate and to processes of using such peptides and their over-expression for the development of  
20 vaccines and as therapeutic agents for stimulation of the immune system for the purpose of killing prostate cancer cells, such as in eliciting cytotoxic T lymphocyte (CTL) responses for the diagnosis, prevention and treatment of cancer.

25

### **BACKGROUND OF THE INVENTION**

The mammalian immune system has evolved a variety of mechanisms to protect the host from cancerous cells, an important  
30 component of this response being mediated by cells referred to as T cells. Cytotoxic T lymphocytes (CTLs) are specialized T cells that function primarily by recognizing and killing cancerous cells or infected cells, but also by secreting soluble molecules referred to as cytokines that can mediate a variety of effects on the immune system.

Evidence suggests that immunotherapy designed to stimulate a tumor-specific CTL response would be effective in controlling cancer. For example, it has been shown that human CTLs recognize sarcomas (Slovin, S. F. et al., *J.Immunol.*, **137**:3042-3048, (1987)), renal cell carcinomas (Schendel, D. J. et al., *J.Immunol.*, **151**:4209-4220, (1993)), colorectal carcinomas (Jacob, L. et al., *Int.J.Cancer*, **71**:325-332, (1997)), ovarian carcinomas (Ioannides, C. G. et al., *J.Immunol.*, **146**:1700-1707, (1991)) (Peoples, G. E. et al., *Surgery*, **114**:227-234, (1993)), pancreatic carcinomas (Peiper, M. et al., *Eur.J.Immunol.*, **27**:1115-1123, (1997); Wolfel, T. et al., *Int.J.Cancer*, **54**:636-644, (1993)), squamous tumors of the head and neck (Yasumura, S. et al., *Cancer Res.*, **53**:1461-1468, (1993)), and squamous carcinomas of the lung (Slingluff, C. L. Jr et al., *Cancer Res.*, **54**:2731-2737, (1994); Yoshino, I. et al., *Cancer Res.*, **54**:3387-3390, (1994)). The largest number of reports of human tumor-reactive CTLs have concerned cancers (Boon, T. et al., *Ann.Rev.Immunol.*, **12**:337-365, (1994)). The ability of tumor-specific CTLs to mediate tumor regression, in both human (Rosenberg, S. A. et al., *N.Engl.J.Med.*, **319**:1676-1680, (1988)) and animal models (Celluzzi, C. M. et al., *J.Exp.Med.*, **183**:283-287, (1996); Mayordomo, J. I. et al., *Nat.Med.*, **1**:1297-1302, (1995); Zitvogel, L. et al., *J.Exp.Med.*, **183**:87-97, (1996)), suggests that methods directed at increasing CTL activity would likely have a beneficial effect with respect to tumor treatment.

In order for CTLs to kill or secrete cytokines in response to a cancer cell, the CTL must first recognize that cell as being cancerous. This process involves the interaction of the T cell receptor, located on the surface of the CTL, with what is generically referred to as an MHC-peptide complex which is located on the surface of the cancerous cell. MHC (major histocompatibility-complex)-encoded molecules have been subdivided into two types, and are referred to as class I and class II MHC-encoded molecules.

In the human immune system, MHC molecules are referred to as human leukocyte antigens (HLA). Within the MHC, located on chromosome six, are three different genetic loci that encode for class I MHC molecules. MHC molecules encoded at these loci are referred to as HLA-A, HLA-B, and HLA-C. The present disclosure involves peptides that are associated with MHC Class I and II type molecules.

The peptides that associate with the MHC molecules can either be derived from proteins made within the cell, in which case they typically associate with class I MHC molecules (Rock, K. L. and Golde, U., *Ann.Rev.Immunol.*, 17:739-779, (1999)) or they can be derived from proteins that are acquired from outside of the cell, in which case they typically associate with class II MHC molecules (Watts, C., *Ann.Rev.Immunol.*, 15:821-850, (1997)). Peptides that evoke a cancer-specific CTL response most typically associate with class I MHC molecules. The peptides that associate with a class I MHC molecule are typically nine amino acids in length, but can vary from a minimum length of eight amino acids to a maximum of fourteen amino acids in length. A class I MHC molecule with its bound peptide, or a class II MHC molecule with its bound peptide, is referred to as an MHC-peptide complex.

The process by which intact proteins are degraded into peptides is referred to as antigen processing. Two major pathways of antigen processing occur within cells (Rock, K. L. and Golde, U., *Ann.Rev.Immunol.*, 17:739-779, (1999); Watts, C., *Ann.Rev.Immunol.*, 15:821-850, (1997)). One pathway, which is largely restricted to cells that are antigen presenting cells such as dendritic cells, macrophages, and B cells, degrades proteins that are typically phagocytosed or endocytosed into the cell. Peptides derived in this pathway typically bind to class II MHC molecules. A second pathway of antigen processing is present in essentially all cells of the body. This second pathway primarily degrades proteins that are made within the

cells, and the peptides derived from this pathway primarily bind to class I MHC molecules. Antigen processing by this latter pathway involves polypeptide synthesis and proteolysis in the cytoplasm. The peptides produced are then transported into the endoplasmic reticulum of the cell, associate with newly synthesized class I MHC molecules, and the resulting MHC-peptide complexes are then transported to the cell surface. Peptides derived from membrane and secreted proteins have also been identified. In some cases these peptides correspond to the signal sequence of the proteins that are cleaved from the protein by the signal peptidase. In other cases, it is thought that some fraction of the membrane and secreted proteins are transported from the endoplasmic reticulum into the cytoplasm where processing subsequently occurs.

Once bound to the MHC molecule and displayed on the surface of a cell, the peptides are recognized by antigen-specific receptors on CTLs. Mere expression of the MHC molecule itself is insufficient to trigger the CTL to kill the target cell if the antigenic peptide is not bound to the MHC molecule. Several methods have been developed to identify the peptides recognized by CTL, each method relying on the ability of a CTL to recognize and kill only those cells expressing the appropriate MHC molecule with the peptide bound to it (Rosenberg, S. A., *Immunity*, 10:281-287, (1999)). Such peptides can be derived from a non-self source, such as a pathogen (for example, following the infection of a cell by a bacterium or a virus) or from a self-derived protein within a cell, such as a cancerous cell. Examples of sources of self-derived proteins in cancerous cells have been reviewed (Gilboa, E., *Immunity*, 11:263-270, (1999); Rosenberg, S. A., *Immunity*, 10:281-287, (1999)) and include: (i) mutated genes; (ii) aberrantly expressed genes such as an alternative open reading frame or through an intron-exon boundary; (iii) normal genes that are selectively expressed in only the tumor and the testis; and (iv) normal differentiation genes that are expressed in the tumor and the normal cellular counterpart.

Four different methodologies have typically been used for identifying the peptides that are recognized by CTLs. These are: (i) the genetic method; (2) motif analysis; (3) SErological analysis of REcombinant cDNA eXpression libraries (SEREX™); and (iv) the analytical chemistry approach or the Direct  
5 Identification of Relevant Epitopes for Clinical Therapeutics (DIRECT™).

The genetic method is an approach in which progressively smaller subsets of cDNA libraries from tumor cells are transfected into cells that express the appropriate MHC molecule but not the tumor-specific epitope. The molecular clones encoding T cell epitopes are identified by their ability  
10 to reconstitute tumor specific T cell recognition of transfected cells. The exact T cell epitope is then identified by a combination of molecular subcloning and the use of synthetic peptides based on the predicted amino acid sequence. Such methods, however, are susceptible to inadvertent identification of cross-reacting peptides, and are not capable of identifying  
15 important post-translational modifications.

Motif analysis involves scanning a protein for peptides containing known class I MHC binding motifs, followed by synthesis and assay of the predicted peptides for their ability to be recognized by tumor-specific CTL. This approach requires prior knowledge of the protein from which the  
20 peptides are derived. This approach is also greatly hampered by the fact that not all of the predicted peptide epitopes are presented on the surface of a cell (Yewdell, J. W. and Bennink, J. R., *Ann.Rev.Immunol.*, 17:51-88, (1999)), thus additional experimentation is required to determine which of the predicted epitopes is useful.

25 The SEREX™ approach relies on using antibodies in the serum of cancer patients to screen cDNA expression libraries for a clone that expresses a protein recognized by the antibody. This methodology presumes that an antibody response will necessarily have developed in the

presence of a T cell response, and thus, the identified clone is a good candidate to encode a protein that can be recognized by T cells.

DIRECT™ involves a combination of cellular immunology and mass spectrometry. This approach involves the actual identification of CTL epitopes by sequencing the naturally occurring peptides associated with MHC molecules. In this approach, cells are first lysed in a detergent solution, the peptides associated with the MHC molecules are purified, and the peptides fractionated by high performance liquid chromatography (HPLC). The peptides are then used to reconstitute recognition by tumor-specific CTLs on a non-tumor cell expressing the appropriate MHC molecules. Sequencing is readily performed by tandem mass spectrometry (Henderson, R. A. et al., *Proc.Natl.Acad.Sci.U.S.A*, **90**:10275-10279, (1993); Hogan, K. T. et al., *Cancer Res.*, **58**:5144-5150, (1998); Hunt, D. F. et al., *Science*, **255**:1261-1263, (1992); Slingsluff, C. L. Jr et al., *J.Immunol.*, **150**:2955-2963, (1993)).

Immunization with cancer-derived, MHC-encoded molecule-associated peptides, or with a precursor polypeptide or protein that contains the peptide, or with a gene that encodes a polypeptide or protein containing the peptide, are forms of immunotherapy that can be employed in the treatment of cancer. These forms of immunotherapy require that immunogens be identified so that they can be formulated into an appropriate vaccine. Although a variety of cancer-derived antigens have been identified (Rosenberg, S. A., *Immunity*, **10**:281-287, (1999)), not all of these are appropriate for broad-based immunotherapy as the expression of some peptides is limited to the tumor derived from a specific patient. Furthermore, the number of MHC molecules from which tumor-derived peptides have been discovered is largely restricted to HLA-A2. Thus, it would be useful to identify additional peptides that complex with MHC molecules other than HLA-A2. Such peptides would be particularly useful

in the treatment of cancer patients who do not express the HLA-A2 molecule. It is also particularly useful to identify antigenic peptides that are derived from different parent proteins. Because an active immune response can result in the outgrowth of tumor cells that have lost the expression of a particular precursor protein for a given antigenic peptide,  
5 it is advantageous to stimulate an immune response against peptides derived from more than one parent protein since the chances of the tumor cell losing the expression of both proteins is the multiple of the chances of losing each of the individual proteins.

10

### BRIEF SUMMARY OF THE INVENTION

In accordance with the present invention, several class I and class II MHC peptides have been identified that are over expressed on prostate  
15 cancer cells. The amino acid sequences of these peptides is provided.

In one aspect, the present invention relates to immunogens, such as immunogenic polypeptides, comprising within their sequences the one or more of the immunogenic peptides disclosed herein, such peptides including  
20 amino acid sequences comprising epitopic sequences selected from the sequences of SEQ ID NO: 1 – 31 and which immunogens facilitate a cytotoxic T lymphocyte (CTL)-mediated immune response against cancers. The present invention also relates to nucleic acid molecules that encode for the polypeptides, and/or the full length proteins from which the polypeptides are  
25 derived, of such immunogens, and which can also be used to facilitate an immune response against cancer.

The present invention provides compositions comprising the immunogen described herein, and polynucleotides that direct the synthesis of such polypeptides, whereby the oligopeptides and polypeptides of such  
30 immunogens are capable of inducing a CTL response against cells



expressing a protein comprising an epitopic sequence of SEQ ID NO: 1 – 31 presented in association with MHC class I or II molecules. The cells are usually cancer cells, especially prostate cancer cells, expressing such proteins.

5

The present invention further relates to proteins containing the peptide sequences disclosed herein.

10 The present invention further relates to polynucleotides comprising the gene coding for a polypeptide of the immunogens disclosed herein.

The present invention also provides vaccines comprising the immunogenic peptides disclosed herein, such as where said peptides are part of the immunogens of the invention, and wherein said vaccines are useful in stimulating the immune system of a recipient against cancerous cells, especially cancer of the prostate.

15 In addition, the present invention also provides methods that comprise contacting a lymphocyte, especially a CTL, with an immunogen of the invention under conditions that induce a CTL response against a tumor cell, and more specifically against a cancer cell. The methods may involve contacting the CTL with the immunogenic peptide *in vivo*, in which case the peptides, polypeptides, and polynucleotides of the invention are used as vaccines, and will be delivered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the immunogen, typically along with an adjuvant or one or more cytokines.

20 Alternatively, the immunogens of the present invention can be used to induce a CTL response *in vitro*. The generated CTL can then be introduced into a patient with cancer, more specifically cancer, colorectal carcinoma, ovarian carcinoma, lung carcinoma, or prostate carcinoma.

Alternatively, the ability to generate CTL *in vitro* can serve as a diagnostic for cancer, colorectal carcinoma, ovarian carcinoma, lung carcinoma, or prostate carcinoma.

5

## DEFINITIONS

As used herein and except as noted otherwise, all terms are defined as given below.

10       The term "peptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are typically 9 to 18 amino acids in length, but can be as short as 3 amino acids in length, and as long as 20 amino acids in length.

15       The term "oligopeptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention as long as the correct epitope or epitopes are maintained. The  
20       oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 14 amino acids in length.

25       The term "polypeptide" designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained. In contrast to the terms peptide or oligopeptide, the term

polypeptide is meant to refer to protein molecules of longer than about 30 residues in length.

A peptide, oligopeptide, protein, or polynucleotide coding for such a molecule is "immunogenic" (and thus an "immunogen" within the present invention) if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a CTL-mediated response. Thus, an "immunogen" would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a CTL response.

A T cell "epitope" is a short peptide molecule that binds to a class I or II MHC molecule and that is subsequently recognized by a T cell. T cell epitopes that bind to class I MHC molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length. T cell epitopes that bind to class II MHC molecules are typically 12-20 amino acids in length. In the case of epitopes that bind to class II MHC molecules, the same T cell epitope may share a common core segment, but differ in the length of the carboxy- and amino- terminal flanking sequences due to the fact that ends of the peptide molecule are not buried in the structure of the class II MHC molecule peptide-binding cleft as they are in the class I MHC molecule peptide-binding cleft.

As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or  
5 gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

The term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. The nucleotide sequence encoding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they  
10 may be synthetically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being  
15 expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and  
20 thus coding for the same amino acid(s).

The term "fragment," when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

25 The term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure

form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

10       The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

      The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

15       The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

      The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations  
5 that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude,  
10 preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, the claimed polypeptide which has a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.

15 The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form." As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000  
20 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in  
25 enriched or isolated form.

The term "active fragment" means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune

response taking the form of stimulating a CTL response within the recipient animal, such as a human. Alternatively, the "active fragment" may also be used to induce a CTL response *in vitro*.

As used herein, the terms "portion," "segment," and "fragment,"  
5 when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would  
10 represent portions, segments or fragments of the starting polypeptide. This means that any such fragment will necessarily contain as part of its amino acid sequence a segment, fragment or portion, that is substantially identical, if not exactly identical, to a sequence of SEQ ID NOs: 1-31. When used in relation to polynucleotides, such terms refer to the products  
15 produced by treatment of said polynucleotides with any of the common endonucleases.

In accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the  
20 sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence  
25 and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding

aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of  
5 bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is  
10 about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the herein above calculated Percent Identity is less than the specified Percent Identity.

Peptide or polypeptide mimetics include peptides or polypeptides  
15 having one or more of the following modifications:

1. sequences wherein one or more of the peptidyl --C(O)NR-- linkages (bonds) have been replaced by a non-peptidyl linkage such as a --CH<sub>2</sub>-carbamate linkage (--CH<sub>2</sub>OC(O)NR--), a phosphonate linkage, a --CH<sub>2</sub>-sulfonamide (-CH<sub>2</sub>--S(O)<sub>2</sub>NR--) linkage, a urea (--NHC(O)NH--) linkage, a --  
20 CH<sub>2</sub> -secondary amine linkage, or with an alkylated peptidyl linkage (--C(O)NR--) wherein R is C1-C4 alkyl;

2. sequences wherein the N-terminus is derivatized to a --NRR<sub>1</sub> group, to a --NRC(O)R group, to a --NRC(O)OR group, to a --NRS(O)<sub>2</sub>R group, to a --NHC(O)NHR group where R and R<sub>1</sub> are hydrogen or C1-C4  
25 alkyl with the proviso that R and R<sub>1</sub> are not both hydrogen;

3. sequences wherein the C terminus is derivatized to --C(O)R<sub>2</sub> where R<sub>2</sub> is selected from the group consisting of C1-C4 alkoxy, and --NR<sub>3</sub>R<sub>4</sub> where R<sub>3</sub> and R<sub>4</sub> are independently selected from the group consisting of hydrogen and C1-C4 alkyl.



Naturally occurring amino acid residues in peptides/polypeptides are abbreviated as recommended by the IUPAC-IUB Biochemical Nomenclature Commission as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I; Methionine is Met or M; Norleucine is Nle; Valine is Val or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gln or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; Glycine is Gly or G, and X is any amino acid. Other naturally occurring amino acids include, by way of example, 4-hydroxyproline, 5-hydroxylysine, and the like.

Synthetic or non-naturally occurring amino acids refer to amino acids which do not naturally occur *in vivo* but which, nevertheless, can be incorporated into the peptide/polypeptide structures described herein. The resulting "synthetic peptide" contain amino acids other than the 20 naturally occurring, genetically encoded amino acids at one, two, or more positions of the peptides. For instance, naphthylalanine can be substituted for tryptophan to facilitate synthesis. Other synthetic amino acids that can be substituted into peptides include L-hydroxypropyl, L-3,4-dihydroxyphenylalanyl, alpha-amino acids such as L-alpha-hydroxylysyl and D-alpha-methylalanyl, L-alpha-methylalanyl, beta.-amino acids, and isoquinolyl. D amino acids and non-naturally occurring synthetic amino acids can also be incorporated into the peptides. Other derivatives include replacement of the naturally occurring side chains of the 20 genetically encoded amino acids (or any L or D amino acid) with other side chains.

As used herein, the term "conservative amino acid substitution" are defined herein as exchanges within one of the following five groups:

- I. Small aliphatic, nonpolar or slightly polar residues:  
Ala, Ser, Thr, Pro, Gly;
- II. Polar, negatively charged residues and their amides:

Asp, Asn, Glu, Gln;

III. Polar, positively charged residues:

His, Arg, Lys;

IV. Large, aliphatic, nonpolar residues:

5 Met Leu, Ile, Val, Cys

V. Large, aromatic residues:

Phe, Tyr, Trp

10 As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents, all as disclosed below.

15

## DETAILED DESCRIPTION OF THE INVENTION

20 The present invention relates to immunogenic peptides, including four class I MHC peptides (SEQ ID NO: 1 – 4) and ten class II MHC peptides, along with their respective nested sets, (SEQ ID NO: 5 – 31), which find use as vaccines or therapeutics to stimulate the immune system to kill prostate cancer cells. Proteins containing the above peptide sequences have also been identified and could also be employed to either stimulate an immune  
25 response against the cancer or function as diagnostic markers of the disease.

In accordance with the present invention there are disclosed specific oligopeptide sequences with amino acid sequences shown in SEQ ID NO: 1 to 31 which represent epitopic peptides (i.e. immunogenic  
30 oligopeptide sequences) of at least about 8 amino acids in length, preferably about 9 to 16 amino acids in length, and no longer than about 20 amino acids in length and present as part of a larger structure, such as

a polypeptide or full length protein. Proteins already known as immunogens in the art, and which comprise one or more of the peptides disclosed herein, are specifically excluded from the present invention.

5           The polypeptides forming the immunogens of the present invention have amino acid sequences that comprise at least one stretch, possibly two, three, four, or more stretches of about 8 to 18 residues in length and which stretches differ in amino acid sequence from the sequences of SEQ ID NO: 1-31 by no more than about 1 to 3, possibly more, amino  
10 acid residues, preferably a conservative amino acid residue, especially amino acids of the same general chemical character, such as where they are hydrophobic amino acids.

Said polypeptides can be of any desired length so long as they have  
15 immunogenic activity in that they are able, under a given set of desirable conditions, to elicit *in vitro* or *in vivo* the activation of cytotoxic T lymphocytes (CTLs) (i.e., a CTL response) against a presentation of a cancer specific protein, especially a prostate cancer specific protein, most especially the proteins disclosed herein as comprising the immunogenic or  
20 epitopic peptides disclosed according to the invention, especially when such proteins are presented along with MHC-1 or MHC-2 proteins, as the case may be, such as where said proteins are presented *in vitro* or *in vivo* by an antigen presenting cell (APC). The proteins and polypeptides forming the immunogens of the present invention can be naturally  
25 occurring or may be synthesized chemically.

The present invention is also directed to an isolated polypeptide, especially one having immunogenic activity, the sequence of which comprises within it one or more stretches comprising any 2 or more of the sequences of SEQ ID NO: 1-31 and in any relative quantities and wherein  
30 said sequences may differ by one or several amino acid residues from the

sequences of SEQ ID NO: 1-31 in any given stretch of 8 to 10 amino acid residues for the MHC class I related sequences and 15 to 19 amino acid residues for the class II related sequences. Thus, within the present invention, such a polypeptide may contain as part of its amino acid sequence, fragments having up to 8 amino acids identical to a sequence of SEQ ID NO: 1-4 such that the polypeptide comprises, in a specific embodiment, 2 segments with at least 8 residues identical to SEQ ID NO: 1 and 1 segment with at least 8 residues identical to SEQ ID NO: 3, or a stretch of at least 15 contiguous residues drawn from SEQ ID NO: 5 – 31, such that the polypeptide comprises, in a specific and non-limiting embodiment, 2 segments with at least 15 residues identical to SEQ ID NO: 5 and 1 segment with at least 15 residues identical to SEQ ID NO: 9.

In other embodiments, other combinations and permutations of the epitopic sequences disclosed herein may be part of an immunogen of the present invention or of such a polypeptide so long as any such polypeptide comprises at least 2 such epitopes, whether such epitopes are different or the same in sequence. Thus, in a specific embodiment, a polypeptide of the present invention may comprise 2 copies of the sequence of SEQ ID NO: 2 at some point or points within its length. Of course, any combinations and permutations of the epitopes disclosed herein, as long as they are present at least two in number in such polypeptides, are expressly contemplated.

All of the epitopic peptides of the invention are ultimately derived from proteins expressed by cancer cells and sequences were identified through the method of Automated High Through-put Sequencing (HTPS).

The first of the peptides has the sequence, YEKILFTEA (SEQ ID NO: 1), and is derived from the 26S Proteasome Regulatory Subunit SI4 protein (residues 186 to 194 inclusive). The second peptide has the sequence,

TYGEIFEKF (SEQ ID NO: 2), and is derived from the NADH-ubiquinone oxidoreductase subunit B14.5B protein (residues 107 to 115 inclusive ). The third peptide has the sequence, GEFGGFGSV (SEQ ID NO: 3), which is found in both the Chromatin assembly factor I P48 subunit protein (residues 103 to 111 inclusive) and the Histone acetyltransferase type B subunit 2 protein (residues 102 to 110 inclusive). The fourth peptide has the sequence, MTDLDIKFQY (SEQ ID NO: 4), and is derived from the Interferon regulatory factor 6 protein (residues 223 to 232 inclusive).

10           The peptides were isolated from prostate cancer cells using the following procedure. Briefly, two cell lines from the same patient, one from prostate cancer cells and the other from healthy prostate tissue, were grown in culture. MHC Class I peptides were immunoaffinity purified with W6/32 antibody from both cell lines. An aliquot of each sample was loaded on a reverse-phase (C18) micro-capillary column and gradient eluted directly into a Fourier transform mass spectrometer. Mass spectra were obtained at a rate of approximately one per second, resulting in a total of roughly 1000 mass spectra per sample. Differential analysis for the two samples was performed: each 25 consecutive mass spectra of class I peptides from the prostate cancer sample were summed, a peak list was generated and compared to the peak list resulting from the corresponding sum of 25 scans recorded on class I peptides isolated from healthy prostate cells. Signals present in the sample from prostate cancer but absent in the normal prostate sample were marked. Further analysis allowed for quantification of the differences for these marked species. Those species that differed by a factor of 9 or more (greater in the cancerous prostate sample by at least a factor of 9) were placed in a candidate list. Species on the candidate list were identified through fragmentation (collision-activated dissociation) on the LCQ ion trap mass spectrometer followed by manual sequencing and database searching.

30

          The present invention also encompasses any amino acid sequence comprising a peptide sequence selected from the group consisting of

YEKILFTEA (SEQ ID NO: 1), TYGEIFEKF (SEQ ID NO: 2), GEFGGFGSV (SEQ ID NO: 3) and MTDLDIKFY (SEQ ID NO: 4), or a peptide identical to one of those four peptides but differing by one, two or three conservative amino acid substitutions. The invention also encompasses peptide mimetics of the peptides YEKILFTEA (SEQ ID NO: 1), TYGEIFEKF (SEQ ID NO: 2), GEFGGFGSV (SEQ ID NO: 3) and MTDLDIKFY (SEQ ID NO: 4). They too could be employed to either stimulate an immune response against the cancer or function as diagnostic markers of the disease.

10 The present invention also relates to 10 class II MHC peptides, including the following. The first of the ten peptides has the sequence, GERAMTKDNNLLGKFELT (SEQ ID NO: 5), and is derived from Heat Shock 70kD Protein 10 (HSC71) (residues 445 to 462 inclusive). The nested set contains the following sequences, EGERAMTKDNNLLGKFE (SEQ ID NO: 6),  
15 GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8).

The second peptide has the sequence, VPGTYKITASARGYNP (SEQ ID NO: 9), and is derived from the Carboxypeptidase D Protein (residues 833 to 848 inclusive). The nested set contains the following sequences, VPGTYKITASARGYNPV (SEQ ID NO: 10), PGTYKITASARGYNP (SEQ ID NO: 11).

The third peptide has the sequence, LNQELRADGTVNQIEG (SEQ ID NO: 12), and is derived from the Apolipoprotein D Protein (residues 57 to 72 inclusive). The nested set contains the following sequences, LNQELRADGTVNQIEGE (SEQ ID NO: 13), QELRADGTVNQIEG (SEQ ID NO: 14), QELRADGTVNQIEGE (SEQ ID NO: 15).

30 The fourth peptide has the sequence, TGQFLYQDSNWASK (SEQ ID NO: 16), and is derived from the Transferrin Receptor Protein (residues 518 to

531 inclusive). The nested set contains the following sequence, TGQFLYQDSNWASKVE (SEQ ID NO: 17).

The fifth peptide has the sequence, NPLEIVSIPDNHGHID (SEQ ID NO: 18), and is derived from the Retinoic Acid Receptor Responder Protein (residues 170 to 185 inclusive ).

The sixth peptide has the sequence, DLPEYQGEPDEISIQK (SEQ ID NO: 19), and is derived from the Putative Oncogene Protein (Accession #AF026816) (residues 4 to 19 inclusive). The nested set contains the following sequences, LPEYQGEPDEISIQK (SEQ ID NO: 20), IDLPEYQGEPDEISIQK (SEQ ID NO: 21).

The seventh peptide has the sequence, IPSVFIGESSANSLKDE (SEQ ID NO: 22), and is derived from the Ring Finger Protein 13 (residues 145 to 161 inclusive). The nested set contains the following sequence, IPSVFIGESSANSLK (SEQ ID NO: 23).

The eighth peptide has the sequence, KQSLTMDPVVKSKEIE (SEQ ID NO: 24), and is derived from the Heat Shock 70kD Protein 4 (Heat Shock 70-related protein APG-2) (residues 754 to 769 inclusive). The nested set contains the following sequences, NKQSLTMDPVVKSKEIE (SEQ ID NO: 25), NKQSLTMDPVVKSKEIEA (SEQ ID NO: 26), KQSLTMDPVVKSKE (SEQ ID NO: 27).

The ninth peptide has the sequence, GRYSISRTEAADLC (SEQ ID NO: 28), wherein the C-terminal C is a cysteinyl-derivative (representing a cysteinyl-cysteine) and is derived from the CD44 Antigen Precursor Protein (phagocytic glycoprotein I) (residues 40 to 53 inclusive). The nested set contains the following sequences, NGRYSISRTEAADLC (SEQ ID NO: 29), KNGRYSISRTEAADLC (SEQ ID NO: 30) (and wherein the C-terminal C of both SEQ ID NO: 29 and 30 represent cysteinylated cysteine).

The tenth peptide has the sequence, DPSYVNVQNLDKARQ (SEQ ID NO: 31), and is derived from the SHC Transforming Protein (p66shc) (residues 424 to 438 inclusive).

5        The peptides were isolated from prostate cancer cells using a procedure substantially similar to that recited above except for the use of MHC Class II peptides in place of class I. In addition, for isolation of the class II peptides (SEQ ID NO: 5 – 31), the initial immunoaffinity step utilized LB3.1 (pan DR) antibody in place of W6/32 antibody and the nested sets (found for  
10       the class II peptides and which are subsets of the identified sequence differing by up to several amino acids at either terminus) were discovered after the source sequence was determined.

Thus, the present invention also relates to these ten class II MHC  
15       peptides and their respective nested sets to either stimulate an immune response against the cancer or function as diagnostic markers of the disease. Accordingly the present invention also encompasses any amino acid sequence comprising a peptide sequence selected from the group consisting of GERAMTKDNNLLGKFELT (SEQ ID NO: 5), EGERAMTKDNNLLGKFE  
20       (SEQ ID NO: 6), GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8), VPGTYKITASARGYNP (SEQ ID NO: 9), VPGTYKITASARGYNPV (SEQ ID NO: 10), PGTYKITASARGYNP (SEQ ID NO: 11), LNQELRADGTVNQIEG (SEQ ID NO: 12), LNQELRADGTVNQIEGE (SEQ ID NO: 13), QELRADGTVNQIEG (SEQ ID  
25       NO: 14), QELRADGTVNQIEGE (SEQ ID NO: 15) TGQFLYQDSNWASK (SEQ ID NO: 16), TGQFLYQDSNWASKVE (SEQ ID NO: 17), NPLEIVSIPDNHGHID (SEQ ID NO: 18), DLPEYQGEPDEISIQK (SEQ ID NO: 19), LPEYQGEPDEISIQK (SEQ ID NO: 20), IDLPEYQGEPDEISIQK (SEQ ID NO: 21), IPSVFIGESSANSLKDE (SEQ ID NO: 22), IPSVFIGESSANSLK  
30       (SEQ ID NO: 23), KQSLTMDPVVKSKEIE (SEQ ID NO: 24), NKQSLTMDPVVKSKEIE (SEQ ID NO: 25), NKQSLTMDPVVKSKEIEA (SEQ ID NO: 26), KQSLTMDPVVKSKE (SEQ ID NO: 27), GRYSISRTEAADLC



(SEQ ID NO: 28), NGRYSISRTEAADLC (SEQ ID NO: 29), KNGRYSISRTEAADLC (SEQ ID NO: 30), DPSYVNVQNLDKARQ (SEQ ID NO: 31) or a peptide identical to one of these peptides but differing by one, two or three conservative amino acid substitutions. The invention also encompasses peptide mimetics of the peptides GERAMTKDNNLLGKFELT (SEQ ID NO: 5), EGERAMTKDNNLLGKFE (SEQ ID NO: 6), GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8), VPGTYKITASARGYNP (SEQ ID NO: 9), VPGTYKITASARGYNPV (SEQ ID NO: 10), PGTYKITASARGYNP (SEQ ID NO: 11), LNQELRADGTVNQIEG (SEQ ID NO: 12), LNQELRADGTVNQIEGE (SEQ ID NO: 13), QELRADGTVNQIEG (SEQ ID NO: 14), QELRADGTVNQIEGE (SEQ ID NO: 15) TGQFLYQDSNWASK (SEQ ID NO: 16), TGQFLYQDSNWASKVE (SEQ ID NO: 17), NPLEIVSIPDNHGHID (SEQ ID NO: 18), DLPEYQGEPDEISIQK (SEQ ID NO: 19), LPEYQGEPDEISIQK (SEQ ID NO: 20), IDLPEYQGEPDEISIQK (SEQ ID NO: 21), IPSVFIGESSANSLKDE (SEQ ID NO: 22), IPSVFIGESSANSLK (SEQ ID NO: 23), KQSLTMDPVVKSKEIE (SEQ ID NO: 24), NKQSLTMDPVVKSKEIE (SEQ ID NO: 25), NKQSLTMDPVVKSKEIEA (SEQ ID NO: 26), KQSLTMDPVVKSKE (SEQ ID NO: 27), GRYSISRTEAADLC (SEQ ID NO: 28), NGRYSISRTEAADLC (SEQ ID NO: 29), KNGRYSISRTEAADLC (SEQ ID NO: 30), DPSYVNVQNLDKARQ (SEQ ID NO: 31). They too could be employed to either stimulate an immune response against the cancer or function as diagnostic markers of the disease.

Oligopeptides as disclosed herein may themselves be prepared by methods well known to those skilled in the art. (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York).

Besides the sequences of SEQ ID NOs:1 - 31, the proteins and polypeptides forming the immunogens of the present invention may also comprise one or more other immunogenic amino acid stretches known to

be associated with cancer, and more specifically with prostate cancer, and which may stimulate a CTL response whereby the immunogenic peptides associate with class I MHC or class 2 MHC molecules, as the case may be.

5           The oligopeptides and polypeptides useful in practicing the present invention may be derived by fractionation of naturally occurring proteins by methods such as protease treatment, or they may be produced by recombinant or synthetic methodologies that are well known and clear to the skilled artisan (Ausubel, F. M. et al, Current Protocols in Molecular  
10   Biology, 1999, John Wiley & Sons, Inc., New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). The polypeptide may comprise a recombinant or synthetic polypeptide that necessarily comprises at least  
15   one of SEQ ID NOs:1-31 which sequences may also be present in multiple copies. Thus, oligopeptides and polypeptides of the present invention may have one, two, three, or more such immunogenic peptides within the amino acid sequence of said oligopeptides and polypeptides, and said immunogenic peptides, or epitopes, may be the same or may be different,  
20   or may have any number of such sequences wherein some of them are identical to each other in amino acid sequence while others within the same polypeptide sequence are different from each other and said epitopic sequences may occur in any order within said immunogenic polypeptide sequence. The location of such sequences within the  
25   sequence of a polypeptide forming an immunogen of the invention may affect relative immunogenic activity. In addition, immunogens of the present invention may comprise more than one protein comprising the amino acid sequences disclosed herein. Such polypeptides may be part of a single composition or may themselves be covalently or non-covalently  
30   linked to each other.

The immunogenic peptides disclosed herein may also be linked directly to, or through a spacer or linker to: an immunogenic carrier such as serum albumin, tetanus toxoid, keyhole limpet hemocyanin, dextran, or a recombinant virus particle; an immunogenic peptide known to stimulate  
5 a T helper cell type immune response; a cytokine such as interferon gamma or GMCSF; a targeting agent such as an antibody or receptor ligand; a stabilizing agent such as a lipid; or a conjugate of a plurality of epitopes to a branched lysine core structure, such as the so-called "multiple antigenic peptide" described in (Posnett, D. N. et al.,  
10 *J.Biol.Chem.*, 263:1719-1725, (1988)); a compound such as polyethylene glycol to increase the half life of the peptide; or additional amino acids such as a leader or secretory sequence, or a sequence employed for the purification of the mature sequence. Spacers and linkers are typically comprised of relatively small, neutral molecules, such as  
15 amino acids and which are substantially uncharged under physiological conditions. Such spacers are typically selected from the group of nonpolar or neutral polar amino acids, such as glycine, alanine, serine and other similar amino acids. Such optional spacers or linkers need not be comprised of the same residues and thus may be either homo- or hetero-  
20 oligomers. When present, such linkers will commonly be of length at least one or two, commonly 3, 4, 5, 6, and possibly as much as 10 or even up to 20 residues (in the case of amino acids). In addition, such linkers need not be composed of amino acids but any oligomeric structures will do as well so long as they provide the correct spacing so as to optimize the  
25 desired level of immunogenic activity of the immunogens of the present invention. The immunogen may therefore take any form that is capable of eliciting a CTL response.

In addition, the immunogenic peptides of the present invention may be part of an immunogenic structure via attachments other than  
30 conventional peptide bonds. Thus, any manner of attaching the peptides of

the invention to an immunogen of the invention, such as an immunogenic polypeptide as disclosed herein, could provide an immunogenic structure as claimed herein. Thus, immunogens, such as proteins of the invention, are structures that contain the peptides disclosed according to the present invention but such immunogenic peptides may not necessarily be attached thereto by the conventional means of using ordinary peptide bounds. The immunogens of the present invention simply contain such peptides as part of their makeup, but how such peptides are to be combined to form the final immunogen is left to the talent and imagination of the user and is in no way restricted or limited by the disclosure contained herein.

The peptides that are naturally processed and bound to an MHC molecule, and which are recognized by a tumor-specific CTL, need not be the optimal peptides for stimulating a CTL response. See, for example, (Parkhurst, M. R. et al., *J.Immunol.*, 157:2539-2548, (1996); Rosenberg, S. A. et al., *Nat.Med.*, 4:321-327, (1998)). Thus, there can be utility in modifying a peptide, such that it more readily induces a CTL response. Generally, peptides may be modified at two types of positions. The peptides may be modified at amino acid residues that are predicted to interact with the class I or class II MHC molecule, in which case the goal is to create a peptide that has a higher affinity for the MHC molecule than does the parent peptide. The peptides can also be modified at amino acid residues that are predicted to interact with the T cell receptor on the CTL, in which case the goal is to create a peptide that has a higher affinity for the T cell receptor than does the parent peptide. Both of these types of modifications can result in a variant peptide that is related to a parent peptide, but which is better able to induce a CTL response than is the parent peptide. As used herein, the term "parent peptide" means an oligopeptide with the amino acid sequence of SEQ ID NO: 1-31.

Thus, immunogens according to the invention may be produced using immunogenic peptides disclosed herein but with appropriate substitutions of one or more amino acids to increase the desired immunological effect, such as by conservative substitutions (conservative meaning as defined  
5 elsewhere herein) or even non-conservative substitutions.

Of course, such substitutions may also involve structures other than the common L-amino acids. Thus, D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure herein. In addition,  
10 amino acids possessing non-standard R groups (i.e., R groups other than those found in the common 20 amino acids of natural proteins) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.

If substitutions at more than one position are found to result in a  
15 peptide with substantially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or syngeneic effects on the antigenicity of the peptide. At most, no more than about 4 or 5 positions within the peptide would simultaneously be substituted.

20 Based on cytotoxicity assays, an epitope is considered substantially identical to the reference peptide if it has at least 10% of the antigenic activity of the reference peptide as defined by the ability of the substituted peptide to reconstitute the epitope recognized by a CTL in comparison to the reference peptide. Thus, when comparing the lytic activity in the linear  
25 portion of the effector:target curves with equimolar concentrations of the reference and substituted peptides, the observed percent specific killing of the target cells incubated with the substituted peptide should be equal to that of the reference peptide at an effector:target ratio that is no greater

than 10-fold above the reference peptide effector:target ratio at which the comparison is being made.

Preferably, when the CTLs specific for a peptide of SEQ ID NOs:1-31 are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1  $\mu$ M, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals.

Thus, the epitopes of the present invention may be identical to naturally occurring tumor-associated or tumor-specific epitopes or may include epitopes that differ by no more than 4 or 5 residues from the reference peptide, as long as they have substantially identical antigenic activity. The immunogens of the invention can also comprise a polypeptide that itself comprises one or more of the epitopic peptides of SEQ ID NOS: 1-31.

The immunogenic peptides and polypeptides of the invention can be prepared synthetically, by recombinant DNA technology, or they can be isolated from natural sources such as tumor cells expressing the parent protein product.

The polypeptides and oligopeptides disclosed herein can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automated peptide synthesizers are commercially available and can be used in accordance with known protocols. See, for example, (Grant, G. A., Synthetic Peptides: A User's

Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York). Fragments of polypeptides of the invention can also be synthesized as intermediates in the synthesis of a larger polypeptide.

5           Recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide or polypeptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell, and cultivated under conditions suitable for expression. These procedures are well known in the art to the skilled  
10   artisan, as described in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York; Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). Thus, recombinantly  
15   produced peptides or polypeptides can be used as the immunogens of the invention.

          The coding sequences for peptides of the length contemplated herein can be synthesized on commercially available automated DNA synthesizers using protocols that are well know in the art. See for example, (Grant, G.  
20   A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York). The coding sequences can also be modified such that a peptide or polypeptide will be produced that incorporates a desired amino acid substitution. The coding sequence  
25   can be provided with appropriate linkers, be ligated into suitable expression vectors that are commonly available in the art, and the resulting DNA or RNA molecule can be transformed or transfected into suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are available, and their selection is left to the skilled artisan.

For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions, and a replication system to provide an expression vector for expression in the desired host cell. For example, promoter sequences  
5 compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast, insect, and mammalian host cells may also be used, employing suitable vectors and control sequences.

10 Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate  
15 for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

More particularly, the present invention also includes recombinant  
20 constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter,  
25 operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pBluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene);



pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

- 5           In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by
- 10   calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). Such cells can routinely be utilized for assaying CTL activity by having said
- 15   genetically engineered, or recombinant, host cells express the immunogenic peptides of the present invention.

- Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by
- 20   Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional
- 25   termination sequences, and 5' flanking non-transcribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

The polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The immunogens of the present invention can be in the form of a composition of one or more of the different immunogens and wherein each immunogen is present in any desired relative abundance. Such compositions can be homogeneous or heterogeneous with respect to the individual immunogenic peptide components present therein, having only one or more than one of such peptides.

The compositions of the present invention may thus be formed of any of the immunogens of the invention wherein said composition comprises any of the peptides of the invention, as well as polypeptides or proteins comprising one or more of the peptides disclosed herein, suspended in a pharmaceutically acceptable carrier, such as any pharmaceutically acceptable diluent or excipient. Thus, the pharmaceutical compositions useful herein also contain a pharmaceutically acceptable carrier, including any suitable diluent or excipient, which includes any pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable carriers include, but are not limited to, liquids such as water, saline, glycerol and ethanol, and the like, including carriers useful in forming sprays for nasal and other respiratory tract delivery or for delivery to the ophthalmic system. A thorough discussion of pharmaceutically acceptable carriers, diluents, and other

excipients is presented in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. current edition).

The immunogenic peptides of the present invention may be used to

5 elicit CTLs *ex vivo* from either healthy individuals or from cancer patients with cancer, such as prostate carcinoma. Such responses are induced by incubating in tissue culture the individual's CTL precursor lymphocytes together with a source of antigen presenting cells and the appropriate immunogenic peptide. Examples of suitable antigen presenting cells

10 include dendritic cells, macrophages, and activated B cells. Typically, the peptide at concentrations between 10 and 40  $\mu\text{g/ml}$ , would be pre-incubated with the antigen presenting cells for periods ranging from 1 to 18 hrs.  $\beta_2$ -microglobulin (4  $\mu\text{g/ml}$ ) can be added during this time period to enhance binding. The antigen presenting cells may also be held at room

15 temperature during the incubation period (Ljunggren, H.-G. et al., *Nature*, **346**:476-480, (1990)) or pretreated with acid (Zeh, H. J., III et al., *Hum.Immunol.*, **39**:79-86, (1994)) to promote the generation of denatured MHC molecules which can then bind the peptide. The precursor CTLs (responders) are then added to the antigen presenting cells to which

20 the immunogenic peptide has bound (stimulators) at responder to stimulator ratios of between 5:1 and 50:1, and most typically between 10:1 and 20:1. The co-cultivation of the cells is carried out at 37°C in RPMI 1640, 10% fetal bovine serum, 2 mM L-glutamine, and IL-2 (5-20 Units/ml). Other cytokines, such as IL-1, IL-7, and IL-12 may also be

25 added to the culture. Fresh IL-2-containing media is added to the cultures every 2-4 days, typically by removing one-half the old media and replenishing it with an equal volume of fresh media. After 7-10 days, and every 7-10 days thereafter, the CTL are re-stimulated with antigen presenting cells to which immunogenic peptide has been bound as

30 described above. Fresh IL-2-containing media is added to the cells throughout their culture as described above. Three to four rounds of

stimulation, and sometimes as many five to eight rounds of stimulation, are required to generate a CTL response that can then be measured *in vitro*. The above described protocol is illustrative only and should not be considered limiting. Many *in vitro* CTL stimulation protocols have been  
5 described and the choice of which one to use is well within the knowledge of the skilled artisan. The peptide-specific CTL can be further expanded to large numbers by treatment with anti-CD3 antibody. For example, see (Riddell, S. R. and Greenberg, P. D., *J.Immunol.Methods*, **128**:189-201, (1990); Walter, E. A. et al., *N.Engl.J.Med.*, **333**:1038-  
10 1044, (1995)).

Antigen presenting cells that are to be used to stimulate a CTL response are typically incubated with peptide of an optimal length, most commonly a nonapeptide, that allows for direct binding of the peptide to the MHC molecule, for example, a class I MHC molecule when utilized a  
15 peptide of SEQ ID NO: 1-4, without additional processing.

It should be noted that, in accordance with the foregoing, larger oligopeptides and polypeptides are generally ineffective in binding to class I MHC molecules as they are not efficiently processed into an appropriately sized peptide in the extracellular milieu. There are a variety  
20 of approaches that are known in the art, however, that allow oligopeptides and polypeptides to be exogenously acquired by a cell, which then allows for their subsequent processing and presentation by a class I MHC molecule.

Representative, but non-limiting examples of such approaches  
25 include electroporation of the molecules into the cell (Harding, C. H. III, *Eur.J.Immunol.*, **22**:1865-1869, (1992)), encapsulation of the molecules in liposomes which are fused to the cells of interest (Reddy, R. et al., *J.Immunol.Methods*, **141**:157-163, (1991)), or osmotic shock in which

the molecules are taken up via pinocytosis (Moore, M. W. et al., *Cell*,  
54:777-785, (1988)). Thus, oligopeptides and polypeptides that comprise  
one or more of the peptides of the invention can be provided to antigen  
presenting cells in such a fashion that they are delivered to the cytoplasm  
5 of the cell, and are subsequently processed to allow presentation of the  
peptides.

Antigen presenting cells suitable for stimulating an *in vitro* CTL  
response that is specific for one or more of the peptides of the invention  
can also be prepared by introducing polynucleotide vectors encoding the  
10 sequences into the cells. These polynucleotides can be designed such that  
they express only a single peptide of the invention, multiple peptides of  
the invention, or even a plurality of peptides of the invention. There are a  
variety of approaches that are known in the art, that allow  
polynucleotides to be introduced and expressed in a cell, thus providing  
15 one or more peptides of the invention to an MHC molecule binding  
pathway. Representative, but non-limiting examples of such approaches  
include the introduction of plasmid DNA through particle-mediated gene  
transfer or electroporation (Tuting, T. et al., *J.Immunol.*, **160**:1139-1147,  
(1998)), or the transduction of cells with an adenovirus expressing the  
20 polynucleotide of interest (Perez-Diez, A. et al., *Cancer Res.*, **58**:5305-  
5309, (1998)). Thus, oligonucleotides that code for one or more of the  
peptides of the invention can be provided to antigen presenting cells in  
such a fashion that the peptides associate with MHC molecules and are  
presented on the surface of the antigen presenting cell, and consequently  
25 are available to stimulate a CTL response.

By preparing the stimulator cells used to generate an *in vitro* CTL  
response in different ways, it is possible to control the peptide specificity of  
CTL response. For example, the CTLs generated with a particular peptide will  
necessarily be specific for that peptide. Likewise, CTLs that are generated

with a polypeptide or polynucleotide expressing or coding for particular peptides will be limited to specificities that recognize those peptides. More broadly, stimulator cells, and more specifically dendritic cells, can be incubated in the presence of the whole protein. As a further alternative, stimulator cells, and more specifically dendritic cells, can be transduced or transfected with RNA or DNA comprising the polynucleotide sequence encoding the protein. Under these alternative conditions, peptide epitopes that are naturally cleaved out of the protein, and which are generated in addition to peptide epitopes of SEQ ID NOs:1-31 can associate with an appropriate class I or class II MHC molecule. The selection of antigen presenting cells and the type of antigen with which to stimulate the CTL, is left to the ordinary skilled artisan.

In specific embodiments, the methods of the present invention include a process for inducing a CTL response *in vitro* that is specific for a tumor cell expressing a peptide as disclosed herein, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has bound as an immunogen one or more of the peptides disclosed according to the invention.

In specific embodiments, the methods of the present invention include a method for inducing a CTL response *in vitro* that is specific for a tumor cell expressing one or more antigens of the kind disclosed herein, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has exogenously acquired an immunogenic oligopeptide or polypeptide that comprises one or more of the peptides disclosed according to the invention.

A yet additional embodiment of the present invention is directed to a process for inducing a CTL response *in vitro* that is specific for a tumor cell expressing the kind of antigens disclosed herein, comprising

contacting a CTL precursor lymphocyte with an antigen presenting cell that is expressing a polynucleotide coding for a polypeptide of the invention and wherein said polynucleotide is operably linked to a promoter.

5           A variety of techniques exist for assaying the activity of CTLs. These techniques include the labeling of target cells with radionuclides such as  $\text{Na}_2^{51}\text{CrO}_4$  or  $^3\text{H}$ -thymidine, and measuring the release or retention of the radionuclides from the target cells as an index of cell death. Such assays are well-known in the art and their selection is left to the skilled  
10   artisan. Alternatively, CTLs are known to release a variety of cytokines when they are stimulated by an appropriate target cell, such as a tumor cell expressing the relevant class I or class II MHC molecule, and the corresponding peptide. Non-limiting examples of such cytokines include IFN- $\gamma$ , TNF $\alpha$ , and GM-CSF. Assays for these cytokines are well known in  
15   the art, and their selection is left to the skilled artisan. Methodology for measuring both target cell death and cytokine release as a measure of CTL reactivity are given in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York).

          After expansion of the antigen-specific CTLs, the latter are then  
20   adoptively transferred back into the patient, where they will destroy their specific target cell. The utility of such adoptive transfer is demonstrated in (North, R. J. et al., Infect.Immun., 67:2010-2012, (1999); Riddell, S. R. et al., Science, 257:238-241, (1992)). In determining the amount of cells to reinfuse, the skilled physician will be guided by the total number  
25   of cells available, the activity of the CTL as measured *in vitro*, and the condition of the patient. Preferably, however, about  $1 \times 10^6$  to about  $1 \times 10^{12}$ , more preferably about  $1 \times 10^8$  to about  $1 \times 10^{11}$ , and even more preferably, about  $1 \times 10^9$  to about  $1 \times 10^{10}$  peptide-specific CTL are infused. Methodology for reinfusing the T cells into a patient are well

known and exemplified in U.S. Patent No. 4,844,893 to Honski, et al., and U.S. Patent No. 4,690,915 to Rosenberg.

5 The peptide-specific CTL can be purified from the stimulator cells prior to infusion into the patient. For example, monoclonal antibodies directed towards the cell surface protein CD8, present on CTL, can be used in conjunction with a variety of isolation techniques such as antibody panning, flow cytometric sorting, and magnetic bead separation to purify the peptide-specific CTL away from any remaining non-peptide specific lymphocytes or from the stimulator cells. These methods are well known in the art, and are their selection is left to the skilled artisan. It should be appreciated that generation of peptide-specific CTLs in this manner, obviates the need for stimulating the CTLs in the presence of tumor. Thus, there is no chance of inadvertently reintroducing tumor cells into the patient.

15 Thus, one embodiment of the present invention relates to a process for treating a subject with a cancer characterized by tumor cells expressing complexes of the antigens as disclosed herein, whereby CTLs produced *in vitro* according to the present invention are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

25 Another embodiment of the present invention is directed to a process for treating a subject with cancer characterized by tumor cells expressing any class I MHC molecule and an epitope of SEQ ID NO: 1 to 4, or any class II molecule and an epitope of SEQ ID NO: 5 to 31, whereby the CTLs are produced *in vitro* and are specific for the epitope or parent protein and are administered in an amount sufficient to destroy the



tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

In the foregoing embodiments the cancer to be treated is preferably a prostate carcinoma.

5           The *ex vivo* generated CTL can be used to identify and isolate the T cell receptor molecules specific for the peptide. The genes encoding the alpha and beta chains of the T cell receptor can be cloned into an expression vector system and transferred and expressed in naïve T cells from peripheral blood, T cells from lymph nodes, or T lymphocyte  
10 progenitor cells from bone marrow. These T cells, which would then be expressing a peptide-specific T cell receptor, would then have anti-tumor reactivity and could be used in adoptive therapy of cancer, and more specifically prostate carcinoma.

          In addition to their use for therapeutic or prophylactic purposes, the  
15 immunogenic peptides of the present invention are useful as screening and diagnostic agents. Thus, the immunogenic peptides of the present invention, together with modern techniques of gene screening, make it possible to screen patients for the presence of genes encoding such peptides on cells obtained by biopsy of tumors detected in such patients.  
20 The results of such screening may help determine the efficacy of proceeding with the regimen of treatment disclosed herein using the immunogens of the present invention.

          Alternatively, the immunogenic peptides disclosed herein, as well as functionally similar homologs thereof, may be used to screen a sample  
25 for the presence of CTLs that specifically recognize the corresponding epitopes. The lymphocytes to be screened in this assay will normally be obtained from the peripheral blood, but lymphocytes can be obtained from

other sources, including lymph nodes, spleen, tumors, and pleural fluid. The peptides of the present invention may then be used as a diagnostic tool to evaluate the efficacy of the immunotherapeutic treatments disclosed herein. Thus, the *in vitro* generation of CTL as described above  
5 would be used to determine if patients are likely to respond to the peptide *in vivo*. Similarly, the *in vitro* generation of CTL could be done with samples of lymphocytes obtained from the patient before and after treatment with the peptides. Successful generation of CTL *in vivo* should then be recognized by a correspondingly easier ability to generate peptide-specific CTL *in vitro* from lymphocytes obtained following treatment in  
10 comparison to those obtained before treatment.

The oligopeptides of the invention, such as SEQ ID NO: 1 - 31, can also be used to prepare class I or class II MHC tetramers that can be used in conjunction with flow cytometry to quantitate the frequency of  
15 peptide-specific CTLs that are present in a sample of lymphocytes from an individual. For example, class I MHC molecules and peptides of SEQ ID NO:1, 2, 3, or 4 would be combined to form tetramers as exemplified in U.S. Patent 5,635,363. Said tetramers would find use in monitoring the frequency of CTLs specific for the combination of MHC and a peptide of  
20 SEQ ID NO:1 in the peripheral blood, lymph nodes, or tumor mass of an individual undergoing immunotherapy with the peptides, proteins, or polynucleotides of the invention, and it would be expected that successful immunization would lead to an increase in the frequency of the peptide-specific CTL. Said tetramers could also be developed for peptides of SEQ  
25 ID NOs:5-31 in combination with the appropriate MHC molecule.

As stated above, a vaccine in accordance with the present invention may include one or more of the hereinabove described polypeptides or active fragments thereof, or a composition, or pool, of immunogenic peptides disclosed herein. When employing more than one

polypeptide or active fragment, such as two or more polypeptides and/or active fragments may be used as a physical mixture or as a fusion of two or more polypeptides or active fragments. The fusion fragment or fusion polypeptide may be produced, for example, by recombinant techniques or  
5 by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.

The immunogenic molecules of the invention, including vaccine compositions, may be utilized according to the present invention for purposes of preventing, suppressing or treating diseases causing the  
10 expression of the immunogenic peptides disclosed herein, such as where the antigen is being expressed by tumor cells. As used in accordance with the present invention, the term "prevention" relates to a process of prophylaxis in which an animal, especially a mammal, and most especially a human, is exposed to an immunogen of the present invention prior to  
15 the induction or onset of the disease process. This could be done where an individual has a genetic pedigree indicating a predisposition toward occurrence of the disease condition to be prevented. For example, this might be true of an individual whose ancestors show a predisposition toward certain types of cancer. Alternatively, the immunogen could be  
20 administered to the general population as is frequently done for infectious diseases. Alternatively, the term "suppression" is often used to describe a condition wherein the disease process has already begun but obvious symptoms of said condition have yet to be realized. Thus, the cells of an individual may have become cancerous but no outside signs of the  
25 disease have yet been clinically recognized. In either case, the term prophylaxis can be applied to encompass both prevention and suppression. Conversely, the term "treatment" is often utilized to mean the clinical application of agents to combat an already existing condition whose clinical presentation has already been realized in a patient. This

would occur where an individual has already been diagnosed as having a tumor.

It is understood that the suitable dosage of an immunogen of the present invention will depend upon the age, sex, health, and weight of the recipient, the kind of concurrent treatment, if any, the frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as determined by the researcher or clinician. The total dose required for any given treatment will commonly be determined with respect to a standard reference dose as set by a manufacturer, such as is commonly done with vaccines, such dose being administered either in a single treatment or in a series of doses, the success of which will depend on the production of a desired immunological result (i.e., successful production of a CTL-mediated response to the antigen, which response gives rise to the prevention and/or treatment desired). Thus, the overall administration schedule must be considered in determining the success of a course of treatment and not whether a single dose, given in isolation, would or would not produce the desired immunologically therapeutic result or effect.

The therapeutically effective amount of a composition containing one or more of the immunogens of this invention, is an amount sufficient to induce an effective CTL response to the antigen and to cure or arrest disease progression. Thus, this dose will depend, among other things, on the identity of the immunogens used, the nature of the disease condition, the severity of the disease condition, the extent of any need to prevent such a condition where it has not already been detected, the manner of administration dictated by the situation requiring such administration, the weight and state of health of the individual receiving such administration, and the sound judgment of the clinician or researcher. Thus, for purposes

of prophylactic or therapeutic administration, effective amounts would generally lie within the range of from 1.0  $\mu$ g to about 5,000  $\mu$ g of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0  $\mu$ g to about 1,000  $\mu$ g of peptide pursuant to a boosting regimen over days, 5 weeks or even months, depending on the recipient's response and as necessitated by subsequent monitoring of CTL-mediated activity within the bloodstream. Of course, such dosages are to be considered only a general guide and, in a given situation, may greatly exceed such suggested dosage regimens where the clinician believes that the 10 recipient's condition warrants more a aggressive administration schedule. Needless to say, the efficacy of administering additional doses, and of increasing or decreasing the interval, may be re-evaluated on a continuing basis, in view of the recipient's immunocompetence (for example, the level of CTL activity with respect to tumor-associated or tumor-specific 15 antigens).

For such purposes, the immunogenic compositions according to the present invention may be used against a disease condition such as cancer by administration to an individual by a variety of routes. The composition may be administered parenterally or orally, and, if parenterally, either 20 systemically or topically. Parenteral routes include subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. One or more such routes may be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time.

25 Generally, vaccines are prepared as injectables, in the form of aqueous solutions or suspensions. Vaccines in an oil base are also well known such as for inhaling. Solid forms which are dissolved or suspended prior to use may also be formulated. Pharmaceutical carriers, diluents and excipients are generally added that are compatible with the active

ingredients and acceptable for pharmaceutical use. Examples of such carriers include, but are not limited to, water, saline solutions, dextrose, or glycerol. Combinations of carriers may also be used. These compositions may be sterilized by conventional, well known sterilization techniques including sterile filtration. The resulting solutions may be packaged for use as is, or the aqueous solutions may be lyophilized, the lyophilized preparation being combined with sterile water before administration. Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.

The concentration of the CTL stimulatory peptides of the invention in pharmaceutical formulations are subject to wide variation, including anywhere from less than 0.01% by weight to as much as 50% or more. Factors such as volume and viscosity of the resulting composition must also be considered. The solvents, or diluents, used for such compositions include water, possibly PBS (phosphate buffered saline), or saline itself, or other possible carriers or excipients.

The immunogens of the present invention may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the immunogenicity and/or half-life of the peptides or polypeptides in serum. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. Liposomes for use in the invention are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood. A variety of methods are available for preparing liposomes as reviewed, for example, by (Coligan, J. E. et al, Current Protocols in Protein Science,

1999, John Wiley & Sons, Inc., New York) and see also U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

Liposomes containing the peptides or polypeptides of the invention can be directed to the site of lymphoid cells where the liposomes then deliver the selected immunogens directly to antigen presenting cells. Targeting can be achieved by incorporating additional molecules such as proteins or polysaccharides into the outer membranes of said structures, thus resulting in the delivery of the structures to particular areas of the body, or to particular cells within a given organ or tissue. Such targeting molecules may a molecule that binds to receptor on antigen presenting cells. For example an antibody that binds to CD80 could be used to direct liposomes to dendritic cells.

The immunogens of the present invention may also be administered as solid compositions. Conventional nontoxic solid carriers including pharmaceutical grades of mannitol, lactose, starch, magnesium, cellulose, glucose, sucrose, sodium saccharin, and the like. Such solid compositions will often be administered orally, whereby a pharmaceutically acceptable nontoxic composition is formed by incorporating the peptides and polypeptides of the invention with any of the carriers listed above. Generally, such compositions will contain 10 - 95% active ingredient, and more preferably 25 - 75% active ingredient.

Aerosol administration is also an alternative, requiring only that the immunogens be properly dispersed within the aerosol propellant. Typical percentages of the peptides or polypeptides of the invention are 0.01% - 20% by weight, preferably 1% - 10%. The use of a surfactant to properly disperse the immunogen may be required. Representative surfactants include the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic,

linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1 - 20% by weight of the composition, preferably 0.25 - 5%. Typical propellants for such administration may include esters and similar chemicals but are by no means limited to these. A carrier, such as lecithin for intranasal delivery, may also be included.

The peptides and polypeptides of the invention may also be delivered with an adjuvant. Adjuvants include, but are not limited to complete or incomplete Freund's adjuvant, Montanide ISA-51, aluminum phosphate, aluminum hydroxide, alum, and saponin. Adjuvant effects can also be obtained by injecting a variety of cytokines along with the immunogens of the invention. These cytokines include, but are not limited to IL-1, IL-2, IL-7, IL-12, and GM-CSF.

The peptides and polypeptides of the invention can also be added to professional antigen presenting cells such as dendritic cells that have been prepared ex vivo. For example, the dendritic cells could be prepared from CD34 positive stem cells from the bone marrow, or they could be prepared from CD14 positive monocytes obtained from the peripheral blood. The dendritic cells are generated ex vivo using cytokines such as GM-CSF, IL-3, IL-4, TNF, and SCF. The cultured DC are then pulsed with peptides at various concentrations using standard methods that are well known in the art. The peptide-pulsed dendritic cells can then be administered either intravenously, subcutaneously, or intradermally, and the immunization may also include cytokines such as IL-2 or IL-12.

The present invention is also directed to a vaccine in which an immunogen of the present invention is delivered or administered in the form of a polynucleotide encoding the a polypeptide or active fragment as



disclosed herein, whereby the peptide or polypeptide or active fragment is produced *in vivo*. The polynucleotide may be included in a suitable expression vector and combined with a pharmaceutically acceptable carrier. For example, the peptides or polypeptides could be expressed in plasmid DNA and nonreplicative viral vectors such as vaccinia, fowlpox, Venezuelan equine encephalitis virus, adenovirus, or other RNA or DNA viruses. These examples are meant to be illustrative only and should not be viewed as self-limiting. A wide variety of other vectors are available and are apparent to those skilled in the art from the description given herein. In this approach, a portion of the nucleotide sequence of the viral vector is engineered to express the peptides or polypeptides of the invention. Vaccinia vectors and methods useful in immunization protocols are described in U.S. Patent No. 4,722,848, the disclosure of which is incorporated herein by reference in its entirety.

Regardless of the nature of the composition given, additional therapeutic agents may also accompany the immunogens of the present invention. Thus, for purposes of treating tumors, compositions containing the immunogens disclosed herein may, in addition, contain other antitumor pharmaceuticals. The use of such compositions with multiple active ingredients is left to the discretion of the clinician.

In addition, the immunogens of the present invention can be used to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in other processes such as affinity chromatography.

A further embodiment of the present invention relates to a process for inducing a CTL response in a subject comprising administering to subjects that express an immunogen of the invention that do not comprise the entire protein expressing the epitopic peptides disclosed

herein in an amount sufficient to induce a CTL response to said tumor cells.

5 A still further embodiment of the present invention relates to a method for inducing a CTL response in a subject, wherein the immunogen is in the form of a polynucleotide, and wherein the epitope or epitopes of said immunogen are selected from a group comprising the peptides disclosed according to the invention, and are coded within a polynucleotide sequence that does not comprise the entire protein coding region, in an amount sufficient to induce a CTL response to tumor cells  
10 expressing such antigenic sites.

Thus, the present invention also relates to a process for inducing a CTL response in a subject, said process comprising administering at least one immunogen as disclosed herein, including combinations thereof, to a mammal, preferably a human being, found to be over-expressing an  
15 epitope of SEQ ID NO: 1 – 31, or over-expressing a protein or polypeptide comprising such epitope, including any of the immunogens disclosed herein, and in an amount sufficient to induce a CTL response to tumor cells expressing said epitope.

20 The sequences of the peptides disclosed herein are in Table 1.

25

Table 1 – Peptides

5	MHC Class I	YEKILFTEA	(SEQ ID NO: 1)	
		TYGEIFEKF	(SEQ ID NO: 2)	
		GEFGGFGSV	(SEQ ID NO: 3)	
		MTDLDIKFQY	(SEQ ID NO: 4)	
10	MHC Class II	GERAMTKDNNLLGKFELT	(SEQ ID NO: 5)	
		EGERAMTKDNNLLGKFE	(SEQ ID NO: 6)	
		GERAMTKDNNLLGK	(SEQ ID NO: 7)	
		ERAMTKDNNLLGKFE	(SEQ ID NO: 8)	
		VPGTYKITASARGYNP	(SEQ ID NO: 9)	
		VPGTYKITASARGYNPV	(SEQ ID NO: 10)	
	15		PGTYKITASARGYNP	(SEQ ID NO: 11)
			LNQELRADGTVNQIEG	(SEQ ID NO: 12)
			LNQELRADGTVNQIEGE	(SEQ ID NO: 13)
			QELRADGTVNQIEG	(SEQ ID NO: 14)
20		QELRADGTVNQIEGE	(SEQ ID NO: 15)	
		TGQFLYQDSNWASK	(SEQ ID NO: 16)	
		TGQFLYQDSNWASKVE	(SEQ ID NO: 17)	
	25		NPLEIVSIPDNHGHID	(SEQ ID NO: 18)
			DLPEYQGEPDEISIQK	(SEQ ID NO: 19)
			LPEYQGEPDEISIQK	(SEQ ID NO: 20)
			IDLPEYQGEPDEISIQK	(SEQ ID NO: 21)
	30		IPSVFIGESSANSLKDE	(SEQ ID NO: 22)
			IPSVFIGESSANSLK	(SEQ ID NO: 23)
			KQSLTMDPVVKSKEIE	(SEQ ID NO: 24)
		NKQSLTMDPVVKSKEIE	(SEQ ID NO: 25)	
35			NKQSLTMDPVVKSKEIEA	(SEQ ID NO: 26)
			KQSLTMDPVVKSKE	(SEQ ID NO: 27)
			GRYSISRTEAADLC	(SEQ ID NO: 28)
			NGRYSISRTEAADLC	(SEQ ID NO: 29)
		KNGRYSISRTEAADLC	(SEQ ID NO: 30)	
		DPSYVNVQNLDKARQ	(SEQ ID NO: 31)	

WHAT IS CLAIMED IS:

1. An immunogen comprising a member selected from the group consisting of:
  - 5 (a) an oligopeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 - 31;
  - (b) an oligopeptide having an amino acid differing by up to three conservative amino acid substitutions from a sequence of (a); and
  - (c) a peptide mimetic of (a).
- 10 2. The immunogen of claim 1 wherein said immunogen is a source protein of SEQ ID NOS: 1 - 31.
3. The immunogen of claim 1 wherein said polypeptide comprises at least two of said oligopeptides.
- 15 4. The immunogen of claim 1 wherein said polypeptide comprises at least three of said oligopeptides.
5. The immunogen of claim 1 wherein said polypeptide comprises at least four of said oligopeptides.
6. The immunogen of claim 1 wherein said oligopeptide differs from the  
20 oligopeptides of SEQ ID NOS: 1 - 31 by no more than 1 amino acid unit.
7. The immunogen of claim 6 wherein said one amino acid difference is the result of substitution of an amino acid in the sequence of the oligopeptide by an amino acid of like character.
8. The immunogen of claim 7 wherein said substitution is the  
25 substitution of one hydrophobic amino acid unit by another hydrophobic amino acid.

9. The immunogen of claim 6 wherein said amino acid difference is the addition or deletion of one amino acid to or from said oligopeptide.

10. A polynucleotide comprising a polynucleotide sequence encoding a polypeptide according to claims 1, 2, 3, 4, 5, 6, 7, 8, and 9.

5           11. The polynucleotide of claim 10 wherein said polynucleotide sequence is DNA.

12. The polynucleotide of claim 10 wherein said polynucleotide sequence is RNA.

13. A vector comprising a polynucleotide of claim 10.

10           14. A mammalian cell comprising the vector of claim 13 and expressing said polynucleotide.

15. A vaccine composition comprising an immunologically active amount of the immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8, or 9.

15           16. An antibody specific for an immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9.

17. A process for inducing a cytotoxic T lymphocyte (CTL) *in vitro* that is specific for a prostate carcinoma comprising contacting a precursor CTL with an immunogen of claim 1 under conditions that generate a CTL response to the tumor cell.

20           18. A process for inducing a CTL response *in vitro* that is specific for a prostate carcinoma comprising contacting a precursor CTL with a mammalian cell of claim 14.

19. A process for treating a subject with cancer characterized by expression of a peptide selected from the group consisting of the peptides of SEQ ID NO: 1 – 31, said process comprising administering CTLs induced by the processes of claims 17 or 18 in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

20. A process for treating a cancer-afflicted subject characterized by tumor cells expressing any class I MHC molecule and a gene coding for an epitopic sequence selected from the group consisting of SEQ ID NO: 1-4, whereby the CTLs of claim 17 are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

21. A process for treating a cancer-afflicted subject characterized by tumor cells expressing any class II MHC molecule and a gene coding for an epitopic sequence selected from the group consisting of SEQ ID NO: 1-31, whereby the CTLs of claim 17 are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

22. The process of claims 19, 20 or 21 wherein said cancer is prostate cancer.

23. A process for inducing a CTL response in a subject, said process comprising administering at least one immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, including combinations thereof, to a mammal over-expressing an epitope of SEQ ID NO: 1 - 31 and in an amount sufficient to induce a CTL response to tumor cells expressing said epitope.

24. The process of claim 25 wherein said mammal is a human being.

## SEQUENCE LISTING

<110> Argonex, Inc.  
UVA Patent Foundation

<120> MHC Peptides Over-Expressed on Prostate Cancer Cells and  
Methods of Use

<130> 26747-26

<150> US/60/212,213

<151> 2000-06-16

<150> US/60/212,165

<151> 2000-06-16

<160> 31

<170> PatentIn version 3.0

<210> 1

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 1

Tyr Glu Lys Ile Leu Phe Thr Glu Ala  
1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 2

Thr Tyr Gly Glu Ile Phe Glu Lys Phe  
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 3

Gly Glu Phe Gly Gly Phe Gly Ser Val  
1 5

<210> 4

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 4

Met Thr Asp Leu Asp Ile Lys Phe Gln Tyr  
1 5 10

<210> 5

<211> 18

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 5

Gly Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu  
1 5 10 15

Leu Thr

<210> 6

<211> 17

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 6

Glu Gly Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe  
1 5 10 15

Glu

<210> 7

<211> 14

<212> PRT

<213> Artificial



&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 7

Gly Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys  
 1 5 10

&lt;210&gt; 8

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 8

Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu  
 1 5 10 15

&lt;210&gt; 9

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 9

Val Pro Gly Thr Tyr Lys Ile Thr Ala Ser Ala Arg Gly Tyr Asn Pro  
 1 5 10 15

&lt;210&gt; 10

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 10

Val Pro Gly Thr Tyr Lys Ile Thr Ala Ser Ala Arg Gly Tyr Asn Pro  
 1 5 10 15

Val

&lt;210&gt; 11

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 11

Pro Gly Thr Tyr Lys Ile Thr Ala Ser Ala Arg Gly Tyr Asn Pro  
1 5 10 15

<210> 12

<211> 16

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 12

Leu Asn Gln Glu Leu Arg Ala Asp Gly Thr Val Asn Gln Ile Glu Gly  
1 5 10 15

<210> 13

<211> 17

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 13

Leu Asn Gln Glu Leu Arg Ala Asp Gly Thr Val Asn Gln Ile Glu Gly  
1 5 10 15

Glu

<210> 14

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 14

Gln Glu Leu Arg Ala Asp Gly Thr Val Asn Gln Ile Glu Gly  
1 5 10

<210> 15

<211> 15

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 15

Gln Glu Leu Arg Ala Asp Gly Thr Val Asn Gln Ile Glu Gly Glu  
1 5 10 15

<210> 16

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 16

Thr Gly Gln Phe Leu Tyr Gln Asp Ser Asn Trp Ala Ser Lys  
1 5 10

<210> 17

<211> 16

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 17

Thr Gly Gln Phe Leu Tyr Gln Asp Ser Asn Trp Ala Ser Lys Val Glu  
1 5 10 15

<210> 18

<211> 16

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 18

Asn Pro Leu Glu Ile Val Ser Ile Pro Asp Asn His Gly His Ile Asp  
1 5 10 15

<210> 19

<211> 16

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 19

Asp Leu Pro Glu Tyr Gln Gly Glu Pro Asp Glu Ile Ser Ile Gln Lys  
 1 5 10 15

<210> 20  
 <211> 15  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 20

Leu Pro Glu Tyr Gln Gly Glu Pro Asp Glu Ile Ser Ile Gln Lys  
 1 5 10 15

<210> 21  
 <211> 17  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 21

Ile Asp Leu Pro Glu Tyr Gln Gly Glu Pro Asp Glu Ile Ser Ile Gln  
 1 5 10 15

Lys

<210> 22  
 <211> 17  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 22

Ile Pro Ser Val Phe Ile Gly Glu Ser Ser Ala Asn Ser Leu Lys Asp  
 1 5 10 15

Glu

<210> 23  
 <211> 15  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 23

Ile Pro Ser Val Phe Ile Gly Glu Ser Ser Ala Asn Ser Leu Lys  
 1 5 10 15

&lt;210&gt; 24

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 24

Lys Gln Ser Leu Thr Met Asp Pro Val Val Lys Ser Lys Glu Ile Glu  
 1 5 10 15

&lt;210&gt; 25

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 25

Asn Lys Gln Ser Leu Thr Met Asp Pro Val Val Lys Ser Lys Glu Ile  
 1 5 10 15

Glu

&lt;210&gt; 26

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

&lt;400&gt; 26

Asn Lys Gln Ser Leu Thr Met Asp Pro Val Val Lys Ser Lys Glu Ile  
 1 5 10 15

Glu Ala

&lt;210&gt; 27

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Epitopic Peptide over-expressed in Prostate Cancer

<400> 27

Lys Gln Ser Leu Thr Met Asp Pro Val Val Lys Ser Lys Glu  
1 5 10

<210> 28

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 28

Gly Arg Tyr Ser Ile Ser Arg Thr Glu Ala Ala Asp Leu Cys  
1 5 10

<210> 29

<211> 15

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 29

Asn Gly Arg Tyr Ser Ile Ser Arg Thr Glu Ala Ala Asp Leu Cys  
1 5 10 15

<210> 30

<211> 16

<212> PRT

<213> Artificial

<220>

<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 30

Lys Asn Gly Arg Tyr Ser Ile Ser Arg Thr Glu Ala Ala Asp Leu Cys  
1 5 10 15

<210> 31

<211> 15

<212> PRT

<213> Artificial

<220>


<223> Epitopic Peptide over-expressed in Prostate Cancer

<400> 31

Asp Pro Ser Tyr Val Asn Val Gln Asn Leu Asp Lys Ala Arg Gln  
1 5 10 15

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/19207

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(7) : Please See Extra Sheet.		
US CL : 424/93.71, 130.1, 185.1; 435/373, 377; 530/326, 327, 328, 350		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
U.S. : 424/93.71, 130.1, 185.1; 435/373, 377; 530/326, 327, 328, 350		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
A_Geneseq_0601, PIR_68, SwissProt_39, SPTREMBL_16		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WEST 2.0, STN(EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH)		
search terms: Inventors' names, prostate, carcinoma, adoptive transfer, immunogen(s)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database A_Geneseq_0601, No. AAW21729, MCPHERSON et al. Nuclear mitototic apparatus interacting protein, NIP-1, abstract, 01 October 1997.	1, 2, 15, 16
X	WO 90/02564 A1 (CODON) 22 March 1990, see entire document.	1, 2, 15, 16
X	Database A_Geneseq_0601, No. AAR03927, DRAGON et al. Proteins homologous to heat shock proteins from Trypanosoma cruzi - used in vaccines and diagnosis for species of eg Mycoplasma or Mycobacteria, abstract, 30 August 1990.	1, 2, 15, 16
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
09 AUGUST 2001	12 OCT 2001	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer MARIANNE DIBRINO 	
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/19207

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

A61K 38/00, 38/04, 39/395, 39/00; A01N 63/00; C07K 7/00, 16/00; C12N 5/06, 5/08



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/19207

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 3-5  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
The "said polypeptide" recited in claims 3-5 lack antecedent basis in base claim 1.
  
3. ☒ Claims Nos.: 10-14, 18, 19 and 22  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.